SCHEMBL1810164

SCHEMBL1810164

O=C(O)c1cc(CCO)on1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.44
POLB P06746 1/20 0.44
RAB9A P51151 9/20 0.44
HPGD P15428 1/20 0.44
NPC1 O15118 7/20 0.43
ALDH1A1 P00352 3/20 0.43
HDAC6 Q9UBN7 1/20 0.41
PTPN1 P18031 2/20 0.41
FDPS P14324 1/20 0.40
HDAC3 O15379 1/20 0.40
MAPK1 P28482 1/20 0.38
S1PR1 P21453 2/20 0.38
S1PR3 Q99500 2/20 0.38
TSHR P16473 1/20 0.38
XBP1 P17861 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17288448 0.85 PPARA (0.46) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL17288997 0.85 PPARA (0.46) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL744240 0.83 NOTUM (0.48) SMN1; SMN2POLBHPGDALDH1A1HDAC6
SCHEMBL27881982 0.82 PTPN1 (0.42) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL31643942 0.82 ALDH1A1 (0.42) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL3771944 0.82 RAB9A (0.58) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL10520054 0.82 RAB9A (0.46) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL15932093 0.79 HDAC3 (0.43) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL11721077 0.79 PPARA (0.54) SMN1; SMN2POLBRAB9AHPGDNPC1
SCHEMBL10924712 0.79 RAB9A (0.55) SMN1; SMN2POLBRAB9AHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133989-A1 SMYD MODULATORS AND USES THEREOF ALT-BIO PTE. LTD. (SG) 2025-06-26 WO disclosed
US-20200148650-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. 2020-05-14 US disclosed
US-20200148650-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. 2020-05-14 US disclosed
US-10428029-B2 Isoxazole carboxamide compounds Epizyme, Inc. (US) 2019-10-01 US disclosed
US-10428029-B2 Isoxazole carboxamide compounds Epizyme, Inc. (US) 2019-10-01 US disclosed
EP-3193603-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. (US) 2017-07-26 EP disclosed
US-20170190676-A1 Isoxazole Carboxamide Compounds Epizyme, Inc. (US) 2017-07-06 US disclosed
US-20170190676-A1 Isoxazole Carboxamide Compounds Epizyme, Inc. (US) 2017-07-06 US disclosed
US-20170190676-A1 Isoxazole Carboxamide Compounds Epizyme, Inc. (US) 2017-07-06 US disclosed
CN-102216291-B Carbamate derivatives containing alkyl-heterocycles, preparation and therapeutic use thereof 赛诺菲-安万特 2016-08-03 CN disclosed
WO-2016040498-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. (US) 2016-03-17 WO disclosed
EP-2356108-B1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-15 EP disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 EP disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 WO disclosed
CN-102216291-A Carbamate derivatives containing alkyl-heterocycles, preparation and therapeutic use thereof SANOFI AVENTIS 2011-10-12 CN disclosed
EP-2356108-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-08-17 EP disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 WO disclosed
WO-2010055267-A1 CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428029-B2 Isoxazole carboxamide compounds SMYD3, SMYD2, SNRPD3 SMN1; SMN2 248/4885POLB 4632/4885RAB9A 759/4885
US-20170190676-A1 Isoxazole Carboxamide Compounds SMYD3, SMYD2, SNRPD3 SMN1; SMN2 248/4885POLB 4632/4885RAB9A 759/4885
US-20200148650-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS SMYD3, SMYD2, SNRPD3 SMN1; SMN2 223/4885POLB 4655/4885RAB9A 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.